Taisuke Hoshi

518 total citations
12 papers, 395 citations indexed

About

Taisuke Hoshi is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Taisuke Hoshi has authored 12 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Taisuke Hoshi's work include Cancer, Hypoxia, and Metabolism (5 papers), Fibroblast Growth Factor Research (4 papers) and Renal cell carcinoma treatment (4 papers). Taisuke Hoshi is often cited by papers focused on Cancer, Hypoxia, and Metabolism (5 papers), Fibroblast Growth Factor Research (4 papers) and Renal cell carcinoma treatment (4 papers). Taisuke Hoshi collaborates with scholars based in Japan, United States and United Kingdom. Taisuke Hoshi's co-authors include Yasuhiro Funahashi, Junji Matsui, Masahiro Matsuki, Yukinori Minoshima, Yuji Yamamoto, Megumi Ikemori‐Kawada, Tohru Tezuka, Yuji Yamanashi, Akane Inoue and Robert W. Burgess and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Taisuke Hoshi

12 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Taisuke Hoshi Japan	6	176	148	90	77	75	12	395
Takahiko Sakaue Japan	10	163 0.9×	79 0.5×	102 1.1×	39 0.5×	101 1.3×	32	377
Ji-Hai Yu China	12	276 1.6×	68 0.5×	143 1.6×	32 0.4×	140 1.9×	19	483
Joycelyn Jie Xin Lee Singapore	11	112 0.6×	200 1.4×	60 0.7×	86 1.1×	239 3.2×	35	479
Gaël S. Roth France	14	205 1.2×	128 0.9×	76 0.8×	46 0.6×	157 2.1×	46	524
Menno T. de Bruijn Netherlands	12	233 1.3×	112 0.8×	90 1.0×	52 0.7×	216 2.9×	18	549
Patrick Reichl Austria	5	232 1.3×	65 0.4×	76 0.8×	34 0.4×	151 2.0×	6	405
Goung‐Ran Yu South Korea	11	282 1.6×	39 0.3×	146 1.6×	48 0.6×	100 1.3×	12	437
Qifei Zou China	11	240 1.4×	130 0.9×	147 1.6×	37 0.5×	136 1.8×	18	527
Ho Young Lim South Korea	8	134 0.8×	178 1.2×	62 0.7×	122 1.6×	175 2.3×	19	481

Countries citing papers authored by Taisuke Hoshi

Since Specialization

Citations

This map shows the geographic impact of Taisuke Hoshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taisuke Hoshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taisuke Hoshi more than expected).

Fields of papers citing papers by Taisuke Hoshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taisuke Hoshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taisuke Hoshi. The network helps show where Taisuke Hoshi may publish in the future.

Co-authorship network of co-authors of Taisuke Hoshi

This figure shows the co-authorship network connecting the top 25 collaborators of Taisuke Hoshi. A scholar is included among the top collaborators of Taisuke Hoshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taisuke Hoshi. Taisuke Hoshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Evans, T.R. Jeffry, Masatoshi Kudo, Ann‐Lii Cheng, et al.. (2024). ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.. Journal of Clinical Oncology. 42(16_suppl). 4094–4094. 1 indexed citations

Majid, Oneeb, Seiichi Hayato, Bojan Lalovic, et al.. (2024). Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). CPT Pharmacometrics & Systems Pharmacology. 13(6). 954–969. 1 indexed citations

Zhu, Andrew X., Josep M. Llovet, Masahiro Kobayashi, et al.. (2021). Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. 39(15_suppl). 4084–4084. 2 indexed citations

Hoshi, Taisuke, Yu Kato, & Yasuhiro Funahashi. (2020). Abstract 2976: Targeting fibroblast growth factor (FGF) signals induced type I IFN regulated response and Immunogenic cell death (ICD) markers in tumor cells with activated FGF signals. Cancer Research. 80(16_Supplement). 2976–2976. 1 indexed citations

Hoshi, Taisuke, et al.. (2019). Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades. Biochemical and Biophysical Research Communications. 513(1). 1–7. 57 indexed citations

Matsuki, Masahiro, Taisuke Hoshi, Yuji Yamamoto, et al.. (2018). Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Medicine. 7(6). 2641–2653. 186 indexed citations

Matsuki, Masahiro, Yusuke Adachi, Yoichi Ozawa, et al.. (2017). Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Cancer Science. 108(4). 763–771. 57 indexed citations

Adachi, Yusuke, Masahiro Matsuki, Atsumi Yamaguchi, et al.. (2016). Abstract 3264: Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models. Cancer Research. 76(14_Supplement). 3264–3264. 2 indexed citations

Mitsuhashi, Kaoru, Takayuki Kimura, Taisuke Hoshi, et al.. (2016). Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth. Cancer Research. 76(14_Supplement). 3262–3262. 1 indexed citations

10.

Tezuka, Tohru, Akane Inoue, Taisuke Hoshi, et al.. (2014). The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses. Proceedings of the National Academy of Sciences. 111(46). 16556–16561. 48 indexed citations

11.

Hoshi, Taisuke, Tohru Tezuka, Kazumasa Yokoyama, et al.. (2013). Mesdc2 plays a key role in cell‐surface expression of Lrp4 and postsynaptic specialization in myotubes. FEBS Letters. 587(23). 3749–3754. 16 indexed citations

12.

Uchiumi, Fumiaki, et al.. (2011). The Effect of Resveratrol on the Werner Syndrome RecQ Helicase Gene and Telomerase Activity. Current Aging Science. 4(1). 1–7. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact